- GB001: Phase 2 studies, LEDA in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in the second half of 2020 - - GB002: Expected to commence Phase 2 TORREY study in pulmonary arterial hypertension in the second half of 2020 - - GB004: Expected to commence

SAN DIEGO --(BUSINESS WIRE)--Aug. 5, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will

SAN DIEGO --(BUSINESS WIRE)--Jun. 1, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its participation

SAN DIEGO --(BUSINESS WIRE)--May 29, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of

SAN DIEGO --(BUSINESS WIRE)--May 19, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its

SAN DIEGO --(BUSINESS WIRE)--May 18, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it intends to

- GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed - - GB001 intellectual property estate strengthened with issuance of new patent by USPTO covering lysine salt drug substance forms - - GB004 completed successful Phase 1b in ulcerative colitis; Phase 2 trial

SAN DIEGO --(BUSINESS WIRE)--May 8, 2020-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report

– Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation and oncology expected in 2020 – – Cash, cash equivalents and marketable securities totaled $401.8 million at year-end 2019 – SAN DIEGO --(BUSINESS WIRE)--Mar.

SAN DIEGO --(BUSINESS WIRE)--Feb. 18, 2020-- Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila